These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1262 related items for PubMed ID: 27487106

  • 1. The status of poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors in ovarian cancer, part 1: olaparib.
    Miller RE, Ledermann JA.
    Clin Adv Hematol Oncol; 2016 Aug; 14(8):619-27. PubMed ID: 27487106
    [Abstract] [Full Text] [Related]

  • 2. Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer.
    Ivy SP, Liu JF, Lee JM, Matulonis UA, Kohn EC.
    Expert Opin Investig Drugs; 2016 Aug; 25(5):597-611. PubMed ID: 26899229
    [Abstract] [Full Text] [Related]

  • 3. Olaparib: an oral PARP-1 and PARP-2 inhibitor with promising activity in ovarian cancer.
    Gunderson CC, Moore KN.
    Future Oncol; 2015 Aug; 11(5):747-57. PubMed ID: 25757679
    [Abstract] [Full Text] [Related]

  • 4. The status of poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors in ovarian cancer, part 2: extending the scope beyond olaparib and BRCA1/2 mutations.
    Miller RE, Ledermann JA.
    Clin Adv Hematol Oncol; 2016 Sep; 14(9):704-11. PubMed ID: 27673289
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Olaparib for the treatment of ovarian cancer.
    Bornstein E, Jimeno A.
    Drugs Today (Barc); 2016 Jan; 52(1):17-28. PubMed ID: 26937492
    [Abstract] [Full Text] [Related]

  • 11. The promising PARP inhibitors in ovarian cancer therapy: From Olaparib to others.
    Chen Y, Du H.
    Biomed Pharmacother; 2018 Mar; 99():552-560. PubMed ID: 29895102
    [Abstract] [Full Text] [Related]

  • 12. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
    Schreiber V, Illuzzi G, Héberlé E, Dantzer F.
    Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693
    [Abstract] [Full Text] [Related]

  • 13. Spotlight on olaparib in the treatment of BRCA-mutated ovarian cancer: design, development and place in therapy.
    Lorusso D, Tripodi E, Maltese G, Lepori S, Sabatucci I, Bogani G, Raspagliesi F.
    Drug Des Devel Ther; 2018 Oct; 12():1501-1509. PubMed ID: 29881257
    [Abstract] [Full Text] [Related]

  • 14. Patient Counseling and Management of Symptoms During Olaparib Therapy for Recurrent Ovarian Cancer.
    Moore KN, Monk BJ.
    Oncologist; 2016 Aug; 21(8):954-63. PubMed ID: 27256873
    [Abstract] [Full Text] [Related]

  • 15. Homologous recombination deficiency and ovarian cancer.
    Ledermann JA, Drew Y, Kristeleit RS.
    Eur J Cancer; 2016 Jun; 60():49-58. PubMed ID: 27065456
    [Abstract] [Full Text] [Related]

  • 16. Olaparib for the treatment of epithelial ovarian cancer.
    McLachlan J, Banerjee S.
    Expert Opin Pharmacother; 2016 Jun; 17(7):995-1003. PubMed ID: 26967466
    [Abstract] [Full Text] [Related]

  • 17. Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer.
    Rafii S, Gourley C, Kumar R, Geuna E, Ern Ang J, Rye T, Chen LM, Shapira-Frommer R, Friedlander M, Matulonis U, De Greve J, Oza AM, Banerjee S, Molife LR, Gore ME, Kaye SB, Yap TA.
    Oncotarget; 2017 Jul 18; 8(29):47154-47160. PubMed ID: 28454085
    [Abstract] [Full Text] [Related]

  • 18. Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial.
    Konstantinopoulos PA, Barry WT, Birrer M, Westin SN, Cadoo KA, Shapiro GI, Mayer EL, O'Cearbhaill RE, Coleman RL, Kochupurakkal B, Whalen C, Curtis J, Farooq S, Luo W, Eismann J, Buss MK, Aghajanian C, Mills GB, Palakurthi S, Kirschmeier P, Liu J, Cantley LC, Kaufmann SH, Swisher EM, D'Andrea AD, Winer E, Wulf GM, Matulonis UA.
    Lancet Oncol; 2019 Apr 18; 20(4):570-580. PubMed ID: 30880072
    [Abstract] [Full Text] [Related]

  • 19. Advances in PARP inhibitors for the treatment of breast cancer.
    Dizdar O, Arslan C, Altundag K.
    Expert Opin Pharmacother; 2015 Apr 18; 16(18):2751-8. PubMed ID: 26485111
    [Abstract] [Full Text] [Related]

  • 20. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.
    Liu FW, Tewari KS.
    Curr Treat Options Oncol; 2016 Mar 18; 17(3):12. PubMed ID: 26931795
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 64.